E Fund Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.09M | Sell |
8,642
-620
| -7% | -$77.9K | 0.05% | 160 |
|
|
2025
Q1 | $1.02M | Buy |
9,262
+1,821
| +24% | +$201K | 0.05% | 166 |
|
|
2024
Q4 | $1.02M | Sell |
7,441
-1,446
| -16% | -$197K | 0.05% | 145 |
|
|
2024
Q3 | $1.02M | Buy |
8,887
+1,568
| +21% | +$181K | 0.05% | 144 |
|
|
2024
Q2 | $1.01M | Buy |
7,319
+4,206
| +135% | +$579K | 0.06% | 127 |
|
|
2024
Q1 | $429K | Sell |
3,113
-983
| -24% | -$136K | 0.03% | 188 |
|
|
2023
Q4 | $540K | Sell |
4,096
-89
| -2% | -$11.7K | 0.03% | 147 |
|
|
2023
Q3 | $471K | Sell |
4,185
-598
| -13% | -$67.3K | 0.04% | 129 |
|
|
2023
Q2 | $451K | Buy |
4,783
+752
| +19% | +$70.9K | 0.04% | 130 |
|
|
2023
Q1 | $408K | Buy |
4,031
+425
| +12% | +$43K | 0.03% | 161 |
|
|
2022
Q4 | $431K | Sell |
3,606
-867
| -19% | -$104K | 0.04% | 165 |
|
|
2022
Q3 | $475K | Sell |
4,473
-170
| -4% | -$18.1K | 0.04% | 134 |
|
|
2022
Q2 | $453K | Buy |
4,643
+1,638
| +55% | +$160K | 0.04% | 163 |
|
|
2022
Q1 | $282K | Buy |
+3,005
| New | +$282K | 0.01% | 220 |
|